Top

memo - Magazine of European Medical Oncology

Published in:

01-06-2018 | comment – reprint

Developments in neuro-oncology

Author: Silvia Hofer, MD

Published in: memo - Magazine of European Medical Oncology | Issue 2/2018

Summary

A short statement on the most recent developments in the neuro-oncology field, including the new WHO Classification of Tumors of the Central Nervous System (2016) and current treatment strategies.

Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20. doi:10.1007/s00401-016-1545-1.CrossRefPubMed

Seystahl K, Gramatzki D, Roth P, Weller M. Pharmacotherapies for the treatment of glioblastoma – current evidence and perspectives. Expert Opin Pharmacother. 2016;17(9):1259–70.CrossRefPubMed

Li X, Wu C, Chen N, et al. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 2016;7(22) doi:10.18632/oncotarget.7961.CrossRefPubMedPubMedCentral

Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374(14):1344–55. doi:10.1056/NEJMoa1500925.CrossRefPubMedPubMedCentral

Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31:337–43CrossRefPubMedPubMedCentral

van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344–50.CrossRefPubMed

Faulkner C, Ellis HP, Shaw A, et al. BRAF fusion analysis in pilocytic astrocytomas: KIAA1549-BRAF 15-9 fusions are more frequent in the midline than within the cerebellum. J Neuropathol Exp Neurol. 2015;74(9):867–72.CrossRefPubMedPubMedCentral

Title: Developments in neuro-oncology
Author: Silvia Hofer, MD
Publication date: 01-06-2018
Publisher: Springer Vienna
Published in: memo - Magazine of European Medical Oncology / Issue 2/2018
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-016-0278-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 2/2018

Educational no. 1: Bone marrow diagnostics in hemato-oncological diseases

Chronic lymphocytic leukemia at ASH 2017

Management of adverse events related to checkpoint inhibition therapy

JAK2V617F allele burden: innovative concept in monitoring of myeloproliferative neoplasms

Chimeric antigen receptor T‑cell therapy—a hematological success story

Pitfalls in the radiological response assessment of immunotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer